NMN Treatment Reverses Vascular Endothelial Dysfunction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Vascular endothelial dysfunction and large elastic artery stiffness associated with aging lead to increased cardiovascular disease risk, primarily due to excessive superoxide production and reduced nitric oxide bioavailability, for which current treatments are inadequate, especially as they are not practical for widespread implementation.

Innovation Solution

Administration of nicotinamide mononucleotide (NMN) as a daily dose, ranging from 1 mg to 25 mg per kg body weight, chronically, to reduce superoxide production, increase nitric oxide bioavailability, and activate SIRT1, thereby improving endothelial function and reducing arterial stiffness.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for vascular endothelial dysfunction are implemented, then some symptomatic relief may be achieved, but they are not practical for widespread implementation due to complexity, cost, or side effects

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidpracticality of treatment

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent employs NMN as a simple, stable, and cost-effective supplement that can be administered orally without complex delivery systems. NMN is a well-characterized molecule with established safety profiles, allowing for widespread implementation through standard pharmaceutical or nutraceutical channels, thus resolving the contradiction between treatment effectiveness and practicality.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Object-affected harmful factors

If oxidative stress is reduced through conventional means, then superoxide production decreases, but current antioxidants are insufficient to fully reverse age-associated vascular dysfunction

Engineering Contradiction:

Improvesuperoxide productionVSAvoidreversal of vascular dysfunction

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent changes the biochemical parameter of NAD+ availability by administering NMN, a direct precursor. This parameter change activates SIRT1 and other NAD+-dependent enzymes that systematically address multiple aspects of vascular aging including superoxide production, endothelial function, and structural protein maintenance, achieving complete reversal of dysfunction rather than partial mitigation.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

NMN serves as an intermediary molecule that converts dietary or supplemental nicotinamide into NAD+, which then activates multiple downstream pathways including SIRT1, SIRT3, and PARPs. This intermediary approach allows a single supplement to coordinate multiple protective mechanisms simultaneously, achieving comprehensive reversal of vascular dysfunction.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If NAD+ levels are increased to activate SIRT1, then endothelial function improves, but the method must be simple enough for chronic administration

Engineering Contradiction:

Improveimprovement in endothelial functionVSAvoidcomplexity of administration

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs NMN as a self-converting precursor that automatically replenishes NAD+ pools through existing cellular enzymatic pathways (NMN adenylyltransferase). The body's own metabolic machinery performs the conversion work, eliminating the need for complex delivery systems, gene therapy vectors, or invasive procedures. This self-service approach enables simple oral or parenteral administration for chronic use.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

NMN treatment effectively reverses age-associated vascular dysfunction by enhancing endothelial function, reducing oxidative stress, and normalizing structural proteins in the arterial wall, thereby improving vascular function and reducing cardiovascular disease risk.

Implementation Method 1

administration of a composition comprising nicotinamide mononucleotide to increase the level of nicotinamide adenine dinucleotide (NAD+) in the subject

Methodology Applied

Scientific EffectNAD+ biosynthesis:

Implementation Method 2

excessive superoxide-associated vascular oxidative stress... Increased vascular production of superoxide occurs with aging and reduces the bioavailability of the vasoprotective and vasodilatory molecule nitric oxide (NO)

Methodology Applied

Scientific EffectOxidative stress reduction: Oxidation

Data Source

PatentUS11433088B2Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide

Publication Date: 2022.09.06 THE REGENTS OF THE UNIVERSITY OF COLORADO

AI summary

Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject.